Kamada (KMDA): Phase II Trial Adds Support For Inhaled AAT Therapy - Jefferies

Jefferies analyst, Raj Denjoy, reiterated his Buy rating on shares of Kamada Ltd. (NASDAQ: KMDA) after the company reported Phase II US trial results for inhaled AAT. The analyst believes that the trial showed statistically significant increases of both AAT & ANEC levels in the lung compared to the placebo. While the study was not designed to show clinical benefits, it showed that inhaled AAT effectively reaches lung tissue, where AAT deficiency manifests over time as worsening lung function. As such, the trail lends crucial support to a mid-17 EU approval and continuing the US clinical program.

No change to the price target of $7.

For an analyst ratings summary and ratings history on Kamada Ltd. click here. For more ratings news on Kamada Ltd. click here.

Shares of Kamada Ltd. closed at $4.89 yesterday.

You May Also Be Interested In

• Cleveland Research Upgrades Dynatrace Inc. (DT) to Buy, 'optimism underlying fundamentals are likely to support upside'
• Bank First National Corp. (BFC) PT Lowered to $87 at Piper Sandler
• Midday movers: Travelers, JB Hunt fall; United Airlines rises